Skip to main content
OpenTrials
Completed

NCT Number: NCT01677208

Danhong Injection in the Treatment of Acute Ischemic Stroke

The purpose of this study is to determine whether Danhong injection is effective in the treatment of acute ischemic stroke.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

The Second Artillery General Hospital of Chinese People's Liberation Army, Beijing, Beijing Municipality, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female or male inpatients
  • Age: 18 - 70 years.
  • Clinical diagnosis of ischemic stroke causing a measurable neurological deficit defined as impairment of language, motor function, cognition and/or gaze, vision or neglect. Ischemic stroke is defined as an event characterized by the sudden onset of an acute focal neurologic deficit presumed to be due to cerebral ischemia after CT scan excludes hemorrhage.
  • Clinical diagnosis of "Xueyu Zheng" (Blood Stasis Syndrome) as the scores of Chinese medicine symptoms scales of "Xueyu Zheng" in ischemic stroke ≥ 20. The Chinese medicine symptoms scales of "Xueyu Zheng" is defined as following (1)hemiplegia-10,(2)numbness of limbs-10,(3) dark face-9,(4)purple or dark lip-8,(5)Roughness of skin-4, (6) pain with fixed point-5, (7) purple or dark tongue-10,(8)ecchymosis on tongue-10,(9)purple sublingual vessel-10,(10)varicose sublingual vessel-8,(11)unsmooth pulse-8,(12)intermittent pulse-1.
  • Onset of symptoms in 1 week prior to initiation of administration of study drug.
  • Clinical diagnosis of cerebral anterior circulation obstruction.
  • 4≤NIHSS<20.
  • Patient is willing to participate voluntarily and to sign a written patient informed consent. Informed consent will be obtained from each patient or the subject's legally authorized representative or relatives, or deferred where applicable, according to the regulatory and legal requirements of the participating centers.

Exclusion criteria

  • Evidence of intracranial hemorrhage (ICH) or other cerebral diseases (eg.vascular malformation, tumor, abscess or multiple sclerosis etc.)on the CT-or MRI-scan.
  • Patients with thrombolysis or endovascular treatment.
  • Known history of allergy or suspected allergic to the drug.
  • Blood glucose 2.8 or > 16.8 mmol / l under the treatment of diabetes or with severe complications due to diabetes (eg. peripheral neuropathy, diabetic gangrene).
  • Liver function impairment with the value of ALT or AST over 1.5-fold of normal value.
  • Renal dysfunction with the value of serum creatinine over 1.5-fold of normal value.
  • Severe cardiac dysfunction on echocardiogram or the grade of heart function over Ⅲ grade.
  • History of prior stroke with mRS ≥2.
  • Complicated with atrial fibrillation.
  • Severe stroke as assessed by appropriate imaging techniques (eg. massive cerebral infarction including more than one lobe of brain or over 1/3 of blood-supply area of middle cerebral artery).
  • Prior disable patients.
  • Hemorrhagic tendency or recent severe or dangerous bleeding in 3 months.
  • Suspected addicted into alcohol or drug abuse.
  • With severe complications that would make the condition more complicated assessed by the investigator.
  • Woman with pregnancy, lactation or positive result of pregnancy test, or women who want to be pregnant in recent 6 months.
  • Woman who is under menstrual period.
  • Patient who is participating in other trials or has been participated in other trials in recent 3 months.

Treatment and study plan

Danhong injection

Drug

A kind of injection made from two kind of Chinese herbs: Salvia miltiorrhiza and Safflower. 40ml Danhong injection added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion

Standard medical care

Procedure

Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2010), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.

Placebo

Drug

0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.

Primary outcomes

  1. Modified Rankin Scale 0-1 (favourable outcome) at Day 90

    Time frame: Day 90

Secondary outcomes

  1. The Score of effect on symptoms of "Xueyue Zheng"(Blood Stasis syndrome)

    Time frame: Day 0, Day7, Day 14, Day 30, Day 60, Day 90

  2. Barthel Index score ≥90

    Time frame: Day 0, Day7, Day 14, Day 30, Day 60, Day 90

  3. NIH stroke scale(NIHSS)

    Time frame: Day 0, Day7, Day 14, Day 30, Day 60, Day 90

    The improvement of the NIHSS score ≥4 or the NIHSS score of 0 to 1

  4. EQ-5D scale

    Time frame: Day 0, Day 7, Day 14, Day 30, Day 60, Day 90

  5. Global disability on mRS at Day 90.

    Time frame: Day 90

    The proportion of patients with mRS ≥3 at Day 90.

  6. Incidence of new-onset major vascular events in 90 days

    Time frame: Day 90

    Major adverse vascular events include ischemic stroke, hemorrhagic stroke, TIA, myocardial infarction and vascular-related death.

  7. Overall mortality at day 90

    Time frame: Day 90

  8. Incidence of severe hemorrhages in 90 days

    Time frame: Day 90

    The definition of "Severe hemorrhages" is in accordance with the GUSTO bleeding criteria, including fatal intracranial hemorrhage (ICH), symptomatic intracerebral hemorrhage (sICH) or which could result in substantial hemodynamic compromise requiring treatment.

  9. Incidence of moderate hemorrhages in 90 days

    Time frame: Day 90

    The definition of "moderate hemorrhages" is in accordance with the GUSTO bleeding criteria, which requires blood transfusion but not results in hemodynamic compromise.

  10. Documentation of adverse events (AEs) and serious AEs

    Time frame: 90 days

Other outcomes

  1. The changes on the profiles of micro-RNA in 96 patients selected from certain centers

    Time frame: Day 0, Day 14, Day 90

  2. The changes on the expression profiles of mRNA in 96 patients selected from certain centers

    Time frame: Day 0, Day 14, Day 90

Sponsors and collaborators

Lead sponsor

China Academy of Chinese Medical Sciences

Other

Collaborators

  • China Food and Drug Administration

Registry information

Official study title

A Randomized, Multi-center, Double-blind, Placebo-controlled Trial of Danhong Injection in the Treatment of Acute Ischemic Stroke

Important dates

Study start
2013
Primary completion
2019
Study completion
2019
First posted
Aug 31, 2012
Registry last updated
Jun 8, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.